Drug interactions for the following drug(s)
Vilanterol may increase the QTc-prolonging activities of Azithromycin.
Applies to: Claritin 10 MG 24 HR Oral Tablet <> Breo Ellipta (fluticasone furoate 200 MCG/ACTUAT / vilanterol 25 MCG/ACTUAT (as vilanterol trifenatate 40 MCG/ACTUAT)) Dry Powder Inhaler, 14 ACTUAT
The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate.
Note: this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
Drug1 (rxcui = 749783, name = {6 (Azithromycin 250 MG Oral Tablet) } Pack, tty = GPCK). Drug2 (rxcui = 1648785, name = 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo], tty = SBD). Drug1 is resolved to Azithromycin, Drug2 is resolved to vilanterol and interaction asserted in DrugBank between Azithromycin and Vilanterol.
Applies to: Claritin 10 MG 24 HR Oral Tablet <> Breo Ellipta (fluticasone furoate 200 MCG/ACTUAT / vilanterol 25 MCG/ACTUAT (as vilanterol trifenatate 40 MCG/ACTUAT)) Dry Powder Inhaler, 14 ACTUAT
Drug1 (rxcui = 206805, name = Loratadine 10 MG Oral Tablet [Claritin], tty = SBD). Drug2 (rxcui = 1648785, name = 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo], tty = SBD). Drug1 is resolved to Loratadine, Drug2 is resolved to Fluticasone propionate and interaction asserted in DrugBank between Loratadine and Fluticasone propionate.
Note: this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.